- When Time Meets Power
- CV Risk Protection
- Tools & Apps
- For Your Practice
- For Your Patients
- Experts’ Interview
- SG_Jardiance Video_Prof Ricardo Fontes Carvalho
- Prof Verma: "Burden of Heart Failure in T2D, how Empagliflozin Helps?"
- Prof Ted Wu: "T2D Patients with A1c Well-controlled and High CV Risk, Would you Add Empagliflozin and Why?"
- Prof Verma: "ESC guidelines 2019- Managing T2D with CV Risk, Changing Perspective with SGLT2i"
- Prof Wu: "Empagliflozin cuts Insulin Need in Patients with T2D"
- Webinar
- For Your Practice
- 5 years of EMPA-REG Outcome
- EMPA-REG OUTCOME a meaningful milestone 50 publications
- Empagliflozin Cardio Renal Metabolic Benefits
- RCJ||Which academic body is conducting the EMPA-KIDNEY study - Prof Groop
- RCJ||How could ERO impact the way we treat patients with CKD - Prof Groop
- RCJ||How EMPA KIDNEY trial is different from other dedicated SLGT2i kidney trials - Prof Groop
- RCJ||Why a dedicated renal outcomes study is impt - Prof Groop video
- RCJ||ERO Renal Data - Analysis in Asian patients
- EK22||EMPA-KIDNEY's Further Results on Annual Rate of Change in eGFR
- Let's Talk
- PTPHF||Guidelines recommend the 4-pillar approach in managing HFrEF. What is a practical approach to implement this?
- PTPHF||How has the HFpEF guidelines evolved with the advent of SGLT2i trials?
- PTPHF||What is the impact of SGLT-2i trials in HFpEF?
- PTPHF||What is the impact on the treatment landscape from the early benefits seen in the EMPEROR trials?
- PTPHF||What do we know about the consistency of the results for empagliflozin across the spectrum of ejection fraction?
- PTPHF||What is the role of empagliflozin in patients hospitalized for heart failure?
- PTPHF||What makes SGLT2i an ideal HF therapy?
- PTPHF||What are the kidney benefits that empagliflozin can offer to heart failure patients?
- Prescribing Information
- Voice of CRM